The American Stock Exchange on Wednesday replaced ImmunexCorp. with Immune Response Corp. in its index of 15 leadingbiotechnology stocks.

Immunex shareholders on Tuesday approved the mergerbetween Immunex of Seattle and Lederle Oncology Corp., a unitof American Cyanamid. Lederle now holds a majority ofImmunex's stock.

Immune Response's stock has been on the rise since May 25,when it closed at $18.25 a share. The stock (NASDAQ:IMNR) wasdown $1 to $26.25 a share on Wednesday. The San Diegocompany will present a preliminary analysis of its Phase II/IIIclinical trials of its putative vaccine for AIDS at next week'sinternational AIDS conference in Berlin.

The Chicago Board Option Exchange Biotechnology Stock Indexnudged ahead of the AMEX index for the first time this week.The CBOE index closed at 120.07 points on Wednesday, down1.45 for the day, while the AMEX index was off 1.14 points,closing at 119.38.

The AMEX index consists of Amgen Inc., Biogen Inc., CambridgeBiotech Inc., Centocor Inc., Chiron Corp., Cytogen Corp., EnzonInc., Gensia Pharmaceuticals Inc., Genzyme Corp., GreenwichPharmaceuticals Inc., Immune Response, The Liposome Co. Inc.,Scios Nova Inc., Synergen Inc. and Xoma Corp.

The CBOE index tracks Amgen, Bio-Technology General Corp.,Biogen, Calgene Inc., Centocor, Chiron, Cytogen, Enzon, EpitopeInc., Gensia, Genzyme, Greenwich Pharmaceuticals, ImmuneResponse, Immunex, Immunomedics Inc., Ivax Corp., TheLiposome Co., North American Vaccine Inc., Synergen and Xoma.


(c) 1997 American Health Consultants. All rights reserved.